StockNews.AI
IMVT
StockNews.AI
154 days

Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

1. Immunovant plans an investor webcast on Phase 3 study results. 2. The focus is on batoclimab for Myasthenia Gravis treatment. 3. Initial results for a Phase 2b study in CIDP will also be discussed. 4. Webcast features CEOs from Immunovant and Roivant. 5. Event scheduled for March 19 at 8:00 a.m. ET.

3m saved
Insight
Article

FAQ

Why Bullish?

Positive investor engagement can drive interest in IMVT, especially with trial results pending.

How important is it?

Key trial results being discussed can significantly influence investor sentiment and stock price.

Why Short Term?

The upcoming webcast may lead to immediate stock reactions based on disclosed results.

Related Companies

ROIVBIIB
March 18, 2025 16:32 ET  | Source: Immunovant Inc. NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Wednesday, March 19th at 8:00 a.m. ET to review results from its Phase 3 study of batoclimab in MG and initial results from its Phase 2b study in CIDP. Pete Salzmann, M.D., MBA, Chief Executive Officer of Immunovant, will be joined by Matt Gline, Chief Executive Officer of Roivant, for the call. Webcast Details The company will host a webcast at 8:00 a.m. ET on Wednesday, March 19. Please click here to register for the event. The live webcast will also be available under the News & Events section of Immunovant’s website. A replay of the event and presentation will be available immediately following the event. About Immunovant, Inc. Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit immunovant.com. Contact:Renee Barnett, MBA Chief Financial Officer Immunovant, Inc. info@immunovant.com

Related News